Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol TIVA for RFCA in Atrial Fibrillation
NCT05397886Completed
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of remimazolam in Atrial fibrillation (AFib) (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Time to eye opening responding to doctor's command up to 1 hour. Started Aug 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05397886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397886.